The present invention relates to a pharmaceutical composition for use in the treatment of prostate pathologies. The present invention further relates to a composition comprising a mixture which comprises or, alternatively, consists of an effective amount of Serenoa repens, Bromelain, Curcumin, Zinc, Lycopene and Selenium, and pharmaceutically acceptable or food grade technological excipients and/or additives. The present invention further relates to a pharmaceutical composition, preferably in the form of softgel capsules, for use in the treatment of disorders or diseases or pathologies connected to and/or deriving from prostatitis and/or benign prostatic hyperplasia.

The present invention relates to a pharmaceutical composition for use in the treatment of prostate pathologies. The present invention further relates to a composition comprising a mixture which comprises or, alternatively, consists of an effective amount of Serenoa repens, Bromelain, Curcumin, Zinc, Lycopene and Selenium, and pharmaceutically acceptable or food grade technological excipients and/or additives. The present invention further relates to a pharmaceutical composition, preferably in the form of softgel capsules, for use in the treatment of disorders or diseases or pathologies connected to and/or deriving from prostatitis and/or benign prostatic hyperplasia.

The present invention relates to a pharmaceutical composition for use in the treatment of prostate pathologies. The present invention further relates to a composition comprising a mixture which comprises or, alternatively, consists of an effective amount of Serenoa repens, Bromelain, Curcumin, Zinc, Lycopene and Selenium, and pharmaceutically acceptable or food grade technological excipients and/or additives. The present invention further relates to a pharmaceutical composition, preferably in the form of softgel capsules, for use in the treatment of disorders or diseases or pathologies connected to and/or deriving from prostatitis and/or benign prostatic hyperplasia.

Methods for treating ovarian cancer comprising: administering to a patient and effective amount of a cannabis extract comprising CBD, wherein preferably, the cannabis extract is administered via a mucosal formulation.

Methods for treating ovarian cancer comprising: administering to a patient and effective amount of a cannabis extract comprising CBD, wherein preferably, the cannabis extract is administered via a mucosal formulation.

A method for treating a noncancerous gynecological disorder comprising: administering to a patient and effective amount of composition comprising a cannabis extract comprising cannabidiol (CBD), wherein the composition is preferably administered in a mucosal form, such as intravaginally.

A method for treating a noncancerous gynecological disorder comprising: administering to a patient and effective amount of composition comprising a cannabis extract comprising cannabidiol (CBD), wherein the composition is preferably administered in a mucosal form, such as intravaginally.

The present invention relates to a pharmaceutical composition comprising at least one Vitamin of the group D, lycopene, at least one flavonoid, at least one terpene and at least one calcium salt of a (C.sub.1-C.sub.3) carboxylic acid for use in the treatment of one or more menstrual disorders selected from the group consisting of Dysmenorrhea and Premenstrual syndrome (PMS).

The present invention relates to a pharmaceutical composition comprising at least one Vitamin of the group D, lycopene, at least one flavonoid, at least one terpene and at least one calcium salt of a (C.sub.1-C.sub.3) carboxylic acid for use in the treatment of one or more menstrual disorders selected from the group consisting of Dysmenorrhea and Premenstrual syndrome (PMS).

The present invention relates to a pharmaceutical composition comprising at least one Vitamin of the group D, lycopene, at least one flavonoid, at least one terpene and at least one calcium salt of a (C.sub.1-C.sub.3) carboxylic acid for use in the treatment of one or more menstrual disorders selected from the group consisting of Dysmenorrhea and Premenstrual syndrome (PMS).